Grand Pharma Introduces a Global Innovative Product for the Treatment of Demodex Blepharitis and Meibomian Gland Disease with Demodex Mites
Grand Pharmaceutical Group Limited (0512.HK, Grand Pharma, together with its subsidiaries, the Group) has entered into a strategic cooperation agreement for product introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc.. After the relevant conditions are met, the Group will acquire the exclusive development, production and commercialization rights in Greater China Region (Mainland China, Hong Kong Special Administrative Region of China, Macau Special Administrative Region of China, and Taiwan Region) for TP-03, a global innovative ophthalmic preparation for the potential treatment of Demodex blepharitis and Meibomian Gland Disease (MGD) in patients with Demodex mites with an upfront payment of USD15 million and a certain amount of registration milestone fees. This strategic cooperation will deepen the strategic plan of the Group’s products in the field of ophthalmology.
TP-03 was approved for commercialization by the United States Food and Drug Administration (FDA) in July 2023. It is the first and only drug approved by the FDA for Demodex blepharitis.
There are positive topline results of TP-03 Phase II clinical research in the United States for the treatment of MGD patients with Demodex mites.
In terms of registration in China, TP-03 has completed a Phase III clinical study. The results show that TP-03 has significant effectiveness in the treatment of Demodex blepharitis with tolerability and favorable safety.
Read more here: https://lnkd.in/gsKDuR5A
Emergency Medicine Clinical Pharmacy Specialist at Wesley Medical Center
2moSo important with ticag about to be generic and so much emphasize on antithrombotic reversal. Great job Serb team!